An FDA advisory panel backed Grail’s Galleri multicancer blood test, voting that probable benefits outweigh risks in a 7–2 decision, with one member abstaining. The debate centered on false positives, false negatives and whether patients might skip guideline-recommended screening after a negative result. Panelists voted unanimously that the test appears safe, but effectiveness support was narrower. The test analyzes methylation patterns from cell-free DNA to detect a cancer signal and infer tissue origin. The panel also emphasized that Galleri should not replace standard screening like breast, cervical, colorectal and lung cancer tests, highlighting the clinical consequence of missed follow-up diagnostic pathways. For biotech leaders, the advisory recommendation represents another step toward commercialization of methylation-based liquid biopsy for broad screening—though real-world impact will depend on how healthcare systems manage confirmatory testing and patient communication.